Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corp
(NQ:
ABUS
)
3.910
-0.110 (-2.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arbutus Biopharma Corp
< Previous
1
2
3
4
5
6
Next >
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
October 24, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
October 18, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
October 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance
May 04, 2023
Via
Benzinga
Recap: Arbutus Biopharma Q1 Earnings
May 04, 2023
Via
Benzinga
Arbutus Biopharma's Earnings Outlook
May 03, 2023
Via
Benzinga
Why Arbutus Biopharma Stock Is Sinking Today
April 25, 2023
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.
Via
The Motley Fool
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
October 05, 2023
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
September 11, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
September 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
3 Stocks to Buy For the COVID Resurgence
September 06, 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
Via
MarketBeat
Exposures
COVID-19
Product Safety
Why Arbutus Biopharma Stock Is Plunging Today
April 25, 2023
Via
Benzinga
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
August 03, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
July 20, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
July 12, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Appoints Two New Executives
July 10, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
June 21, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
June 07, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at Jefferies Healthcare Conference
May 31, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present at JMP Securities Life Sciences Conference
May 09, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
May 04, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
April 27, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
April 25, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
April 20, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
April 18, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
April 12, 2023
Via
Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
April 04, 2023
Via
Benzinga
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
April 04, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
March 16, 2023
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.